MX374245B - Derivados de naftiridinadiona. - Google Patents

Derivados de naftiridinadiona.

Info

Publication number
MX374245B
MX374245B MX2016015856A MX2016015856A MX374245B MX 374245 B MX374245 B MX 374245B MX 2016015856 A MX2016015856 A MX 2016015856A MX 2016015856 A MX2016015856 A MX 2016015856A MX 374245 B MX374245 B MX 374245B
Authority
MX
Mexico
Prior art keywords
naphthyridinedione
derivatives
naphthyridinedione derivatives
medicaments
medicament
Prior art date
Application number
MX2016015856A
Other languages
English (en)
Other versions
MX2016015856A (es
Inventor
Carsten Spanka
Juergen Reinhardt
Niko Schmiedeberg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016015856A publication Critical patent/MX2016015856A/es
Publication of MX374245B publication Critical patent/MX374245B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I'): (Ver Fórmula) o a una sal del mismo, en donde los sustituyentes son como se definen en la memoria descriptiva; a su preparación, a su uso como un medicamento, y a los medicamentos que lo comprenden.
MX2016015856A 2014-06-03 2015-06-02 Derivados de naftiridinadiona. MX374245B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170976 2014-06-03
PCT/IB2015/054174 WO2015186063A1 (en) 2014-06-03 2015-06-02 Naphthyridinedione derivatives

Publications (2)

Publication Number Publication Date
MX2016015856A MX2016015856A (es) 2017-04-25
MX374245B true MX374245B (es) 2025-03-05

Family

ID=50841689

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015856A MX374245B (es) 2014-06-03 2015-06-02 Derivados de naftiridinadiona.

Country Status (28)

Country Link
US (2) US10138232B2 (es)
EP (1) EP3152209B1 (es)
JP (2) JP6343034B2 (es)
KR (1) KR101905295B1 (es)
CN (1) CN106459043B (es)
AP (1) AP2016009545A0 (es)
AR (1) AR100706A1 (es)
AU (2) AU2015270125B2 (es)
BR (1) BR112016027383A8 (es)
CA (1) CA2950724A1 (es)
CL (1) CL2016003081A1 (es)
CR (1) CR20160565A (es)
CU (1) CU24438B1 (es)
EA (1) EA030374B1 (es)
EC (1) ECSP16096831A (es)
ES (1) ES2731802T3 (es)
GT (1) GT201600252A (es)
IL (1) IL248773B (es)
MX (1) MX374245B (es)
MY (1) MY178379A (es)
PE (1) PE20170086A1 (es)
PH (2) PH12016502293A1 (es)
SG (1) SG11201609209YA (es)
SV (1) SV2016005331A (es)
TN (1) TN2016000490A1 (es)
TW (1) TWI688565B (es)
UY (1) UY36150A (es)
WO (1) WO2015186063A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743183T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
ES2731802T3 (es) 2014-06-03 2019-11-19 Novartis Ag Derivados de naftiridinodiona como supresores de mutaciones sin sentido
WO2015186062A1 (en) * 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2020022375A1 (ja) 2018-07-24 2020-01-30 ソニーセミコンダクタソリューションズ株式会社 半導体装置
WO2024161623A1 (ja) * 2023-02-03 2024-08-08 株式会社 RINAT Imaging リードスルー薬、リードスルー用組み合わせ剤及び核酸プローブの使用
CN117756607A (zh) * 2023-12-01 2024-03-26 陕西煤业化工技术研究院有限责任公司 一种二甲酚馏分异构化生产高值二甲酚的工艺及系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) * 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6016875A (en) * 1998-02-10 2000-01-25 Case Corporation Gain adaptation control for hydraulic systems
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP3345895B1 (en) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
LT2390255T (lt) 2006-04-03 2016-10-25 Technion Research & Development Foundation Ltd. Nauji aminoglikozidai ir jų panaudojimas genetinių sutrikimų gydyme
CN101563349A (zh) 2006-08-23 2009-10-21 神经能质公司 经卤烷基取代的嘧啶酮衍生物
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
WO2012016930A1 (en) 2010-08-05 2012-02-09 Universite De Droit Et Sante De Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
CN107569487A (zh) 2012-12-13 2018-01-12 诺华股份有限公司 作为无义突变抑制子的嘧啶并[4,5‑b]喹啉‑4,5(3H,10H)‑二酮
ES2743183T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
ES2731802T3 (es) 2014-06-03 2019-11-19 Novartis Ag Derivados de naftiridinodiona como supresores de mutaciones sin sentido
WO2015186062A1 (en) 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES

Also Published As

Publication number Publication date
SG11201609209YA (en) 2016-12-29
CU24438B1 (es) 2019-09-04
AP2016009545A0 (en) 2016-11-30
EP3152209B1 (en) 2019-03-20
PH12018501709A1 (en) 2019-08-14
WO2015186063A1 (en) 2015-12-10
PE20170086A1 (es) 2017-03-17
TN2016000490A1 (en) 2018-04-04
MX2016015856A (es) 2017-04-25
GT201600252A (es) 2018-12-18
US20190248784A1 (en) 2019-08-15
AR100706A1 (es) 2016-10-26
CL2016003081A1 (es) 2017-06-09
US20150344476A1 (en) 2015-12-03
EA030374B1 (ru) 2018-07-31
KR101905295B1 (ko) 2018-10-05
AU2015270125A1 (en) 2016-11-24
IL248773B (en) 2019-12-31
ES2731802T3 (es) 2019-11-19
CR20160565A (es) 2017-03-10
IL248773A0 (en) 2017-01-31
EP3152209A1 (en) 2017-04-12
CN106459043B (zh) 2018-12-28
KR20160148679A (ko) 2016-12-26
BR112016027383A2 (pt) 2017-08-15
PH12016502293B1 (en) 2017-02-13
TWI688565B (zh) 2020-03-21
EA201692270A1 (ru) 2017-03-31
BR112016027383A8 (pt) 2021-07-20
AU2015270125B2 (en) 2017-10-19
JP2018138609A (ja) 2018-09-06
SV2016005331A (es) 2018-08-20
US10138232B2 (en) 2018-11-27
JP2017516821A (ja) 2017-06-22
ECSP16096831A (es) 2018-04-30
CN106459043A (zh) 2017-02-22
UY36150A (es) 2016-01-29
AU2018200421A1 (en) 2018-02-08
CU20160182A7 (es) 2017-03-03
TW201625610A (zh) 2016-07-16
CA2950724A1 (en) 2015-12-10
MY178379A (en) 2020-10-09
PH12016502293A1 (en) 2017-02-13
JP6343034B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
TW201613911A (en) Heterocyclic compounds and uses thereof
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12018501709A1 (en) Naphthridinedione derivatives
EA201790785A1 (ru) Производные тетрагидроизохинолина
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX378732B (es) Formas solidas novedosas
IN2015DN03998A (es)
MX373320B (es) Compuestos inhibidores de pde2.
PH12016501462A1 (en) Neprilysin inhibitors
MX376283B (es) Compuestos de imidazopiridazina.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
IN2014DN10449A (es)
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
MX2017007380A (es) Compuestos organicos.

Legal Events

Date Code Title Description
FG Grant or registration